Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Lilly 2Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Lilly 2Q

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Lilly

2Q Revenues: $5.2 billion (+11%)

2Q Earnings: $958.8 million (+44%)

YTD Revenues: $10.0 billion (+12%)

YTD Earnings: $2.0 billion (+73%)

Comments: Alimta, Byetta, Cialis, Cymbalta, Forteo, Strattera, Symbyax, Xigris and Yentreve, collectively grew 21% to $1.8 billion, and accounted for 35% of total sales, up from 32% in 2Q07. Zyprexa sales in the quarter were $1.2 billion (+2%). Cymbalta sales were $654.4 million (+26%). Gemzar sales were $440.1 million (+11%). Humalog sales were up 22% to $437.9 million. Cialis sales were $362.2 million (+24%). Alimta sales were up 33% to $275.0 million. Byetta sales were up 25% to $194.7 million in quarter. The company recognized a charge of $35.0 million in quarter for acquired in-process R&D associated with the in-licensing transaction with TransPharma Medical. Restructuring costs and other charges were $88.9 million in the quarter, primarily associated with strategic exit activities related to manufacturing operations.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters